nach oben

Erschienen in:

27.08.2018 | Review articles

Regulation of geminin by neuropeptide Y in vascular smooth muscle cell proliferation

A current review

verfasst von: S.-y. Liang, Y.-l. Zhou, Dr. M.-q. Shu, Dr. S. Lin

Erschienen in: Herz | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Geminin, a key regulator of DNA replication licensing in the cell cycle, plays an essential role in determining the fate of cells via suppression of cell proliferation and cellular differentiation. Neuropeptide Y (NPY) intensifies the proliferation of vascular smooth muscle cells (VSMCs) directly by binding with Y1 receptors. In vitro experiments have shown that stimulation of NPY on VSMCs via regulation of geminin is a double-edged sword. Given that the proliferation and the phenotypic transformation of VSMCs increase the risk for progression of atherosclerosis, we focus on the role of geminin interference in determining the fate of VSMCs. Furthermore, we discuss the therapeutic potential of peripheral neurotransmitter interference, thus pointing toward future research directions in the treatment of atherosclerosis.

Legein B et al (2013) Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci 70(20):3847–3869CrossRef

Yahagi K et al (2016) Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol 13(2):79–98CrossRef

Dzau VJ, Braun-Dullaeus RC, Sedding DG (2002) Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8(11):1249–1256CrossRef

Zhang Y et al (2014) Geminin interference facilitates vascular smooth muscle cell proliferation by upregulation of CDK-1. Cardiovasc Drugs Ther 28(5):407–414CrossRef

McGarry TJ, Kirschner MW (1998) Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell 93(6):1043–1053CrossRef

Kroll KL et al (1998) Geminin, a neuralizing molecule that demarcates the future neural plate at the onset of gastrulation. Development 125(16):3247–3258PubMed

Seo S et al (2005) Geminin regulates neuronal differentiation by antagonizing Brg1 activity. Genes Dev 19(14):1723–1734CrossRef

Yasunaga S et al (2016) Role of Geminin in cell fate determination of hematopoietic stem cells (HSCs). Int J Hematol 104(3):324–329. https://doi.org/10.1007/s12185-016-2060-9 CrossRefPubMed

Wohlschlegel JA et al (2000) Inhibition of eukaryotic DNA replication by geminin binding to Cdt1. Science 290(5500):2309–2312CrossRef

10.

Saxena S, Dutta A (2005) Geminin-Cdt1 balance is critical for genetic stability. Mutat Res 569(1–2):111–121CrossRef

11.

Jiang ZQ et al (2017) Different effects of neuropeptide Y on proliferation of vascular smooth muscle cells via regulation of Geminin. Mol Cell Biochem 433(1-2):205–211. https://doi.org/10.1007/s11010-017-3028-7 CrossRefPubMed

12.

Warner MR et al (1991) Sympathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart. Circ Res 69(2):455–465CrossRef

13.

Herring N (2015) Autonomic control of the heart: going beyond the classical neurotransmitters. Exp Physiol 100(4):354–358CrossRef

14.

Zhu P et al (2016) The role of neuropeptide Y in the pathophysiology of atherosclerotic cardiovascular disease. Int J Cardiol 220:235–241CrossRef

15.

Zukowska Z (2005) Atherosclerosis and angiogenesis: what do nerves have to do with it? Pharmacol Rep 57(Suppl):229–234PubMed

16.

Karamitros D et al (2014) Life without geminin. Cell Cycle 9(16):3201–3205CrossRef

17.

Suchyta M, Miotto B, McGarry TJ (2015) An inactive geminin mutant that binds cdt1. Genes (Basel) 6(2):252–266CrossRef

18.

Zhou B et al (2012) Structural basis for homeodomain recognition by the cell-cycle regulator Geminin. Proc Natl Acad Sci USA 109(23):8931–8936CrossRef

19.

Ohtsubo M et al (2008) Polycomb-group complex 1 acts as an E3 ubiquitin ligase for Geminin to sustain hematopoietic stem cell activity. Proc Natl Acad Sci USA 105(30):10396–10401CrossRef

20.

Ohno Y et al (2010) Hoxb4 transduction down-regulates Geminin protein, providing hematopoietic stem and progenitor cells with proliferation potential. Proc Natl Acad Sci USA 107(50):21529–21534CrossRef

21.

Ohno Y et al (2013) Hoxa9 transduction induces hematopoietic stem and progenitor cell activity through direct down-regulation of geminin protein. PLoS ONE 8(1):e53161CrossRef

22.

Haruki T et al (2011) Geminin expression in small lung adenocarcinomas: implication of prognostic significance. Lung Cancer 71(3):356–362CrossRef

23.

DePamphilis ML (2011) Spotlight on geminin. Breast Cancer Res 13(3):109CrossRef

24.

Liu E et al (2004) Cyclin-dependent kinases phosphorylate human Cdt1 and induce its degradation. J Biol Chem 279(17):17283–17288CrossRef

25.

Nishitani H et al (2001) The human licensing factor for DNA replication Cdt1 accumulates in G1 and is destabilized after initiation of S‑phase. J Biol Chem 276(48):44905–44911CrossRef

26.

Guo J, Sun N (2013) Cell cycle regulator geminin is dispensable for the proliferation of vascular smooth muscle cells. Sci China Life Sci 56(8):731–738CrossRef

27.

Rensen SS, Doevendans PA, van Eys GJ (2007) Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J 15(3):100–108CrossRef

28.

Hao H, Gabbiani G, Bochaton-Piallat ML (2003) Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 23(9):1510–1520CrossRef

29.

Dimaki M et al (2013) Cell cycle-dependent subcellular translocation of the human DNA licensing inhibitor geminin. J Biol Chem 288(33):23953–23963CrossRef

30.

Masuo K et al (2010) The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res 33(6):521–528CrossRef

31.

Schroeder C, Jordan J (2012) Norepinephrine transporter function and human cardiovascular disease. Am J Physiol Heart Circ Physiol 303(11):H1273–H1282CrossRef

32.

Katz DP et al (2016) Benzylpiperazine: “a messy drug”. Drug Alcohol Depend 164:1–7CrossRef

33.

Zukowska-Grojec Z et al (1998) Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 75–76:231–238CrossRef

34.

Saleh Al-Shehabi T, Iratni R, Eid AH (2016) Anti-atherosclerotic plants which modulate the phenotype of vascular smooth muscle cells. Phytomedicine 23(11):1068–1081CrossRef

35.

Abe K, Tilan JU, Zukowska Z (2007) NPY and NPY receptors in vascular remodeling. Curr Top Med Chem 7(17):1704–1709CrossRef

36.

Crnkovic S et al (2014) NPY/Y(1) receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension. Br J Pharmacol 171(16):3895–3907CrossRef

37.

Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362(6423):801–809CrossRef

Titel: Regulation of geminin by neuropeptide Y in vascular smooth muscle cell proliferation
A current review
verfasst von: S.-y. Liang
Y.-l. Zhou
Dr. M.-q. Shu
Dr. S. Lin
Publikationsdatum: 27.08.2018
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 8/2019
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-018-4721-3

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Regulation of geminin by neuropeptide Y in vascular smooth muscle cell proliferation

A current review

Abstract

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Neue ESC-Leitlinie „Diabetes und kardiovaskuläre Erkrankungen“ – ein Paradigmenwechsel

Mutations in genes associated with either myopathy or noncompaction

Delayed vs. immediate stenting in STEMI with a high thrombus burden

Evaluation of myocardial viability in myocardial infarction patients by magnetic resonance perfusion and delayed enhancement imaging

Europäische Leitlinien zu Lipiden – was ist neu?

ESC-Leitlinie zum chronischen Koronarsyndrom – was ist neu oder besonders wichtig?

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie